Alcobra News Flow Ramps in 2H13; Should Provide Liquidity and Visibility
Insights - Recent-IPO Alcobra Ltd. (ADHD) has been on a tear over the last 10 days, and while the stock has gotten away from us since we … Continue Reading
PremiumAuthor Archives: Jake King
Curis’ Differentiated Oncology Approach Is Worth More than the Market Suggests
Long Ideas - Update: On the morning of July 15th, Curis announced that the European Commission granted the conditional approval of Erivedge (vismodegib) for the treatment of adult patients with … Continue Reading
Read nowAnother New Marketing Effort Spotlights Questcor’s Long-Term Potential
Long Ideas - Questcor (QCOR) is getting some love Thursday morning following an announcement that the company will be pursuing the commercialization of H.P. Acthar Gel in respiratory … Continue Reading
Read nowInvestors Have Completely Overlooked diaDexus’ Asymmetric Risk/Reward
Long Ideas - With the majority of statins now generic, pharmaceutical companies are on the hunt for the next blockbuster cardiovascular drug to replace what was once a … Continue Reading
Read nowBioDelivery Sciences’ Debt Deal Puts Inflection Points Within Range
Long Ideas - BioDelivery Sciences (BDSI) on Monday entered into a $20 million senior secured loan with MidCap Financial and issued to the group a warrant to purchase … Continue Reading
Read nowAchillion is Tripped Up but The Negativity is Overdone
Long Ideas - On Monday after the close, Achillion Pharmaceuticals (ACHN) revealed that the FDA has placed a partial clinical hold on the development of lead candidate sovaprevir … Continue Reading
Read nowThis Wet-AMD Play Worked Beautifully
Recap - Split-adjusted, Ohr Pharma (OHRP) is up 61% since PropThink covered the small-cap drug developer in mid-March. Some investors remain skeptical of the company’s lead asset, … Continue Reading
Read now